史家海 教授
科学创始人
Prof. Jiahai Shi,
Scientific Co-founder
史家海，新加坡国立大学医学院助理教授（博士生导师），为厦门大学学士，新加坡国立大学的博士和麻省理工大学的博士后。二十年源头创新药开发经验。曾参与戊型肝炎病毒疫苗（益可宁）开发。博士期间证明SARS冠状病毒主蛋白酶的二聚体界面是潜在的病毒药物靶点。博士后期间师从Harvey Lodish，参与开创第一代合成红细胞治疗平台。利用此技术，Rubius Therapeutic于2018在纳斯达克上市，当时市值近20亿美元。现参与开创合成红细胞外囊泡基因治疗，并利用此技术成为Carmine Therapeutic的共同科学创始人和科学顾问。2020年7月，Carmine和武田制药达成总额为9亿美元的预付款和里程碑付款的协议，共同开发2种基因疗法。现进一步开发第二代合成红细胞治疗平台，并利用该技术成为Carcell Biopharma的科学创始人和科学顾问， 并于2021年11月得到1600万美元的天使轮投资。我们又开发出世界首次利用可繁养鲨鱼免疫制备鲨鱼纳米抗体的平台技术，并成立jotbody 聚焦骆驼和鲨鱼纳米抗体发现服务和生命科学工具。
Dr. Jiahai Shi received his Bachelor’s Degree in Biological Sciences from Xiamen University in 2002. After graduation, he was awarded a full PhD scholarship to join Dr. Jianxing Song’s lab at the National University of Singapore. To explore new areas of research, and to broaden his expertise during his post-doctoral training, Dr. Shi joined the laboratory of Dr. Harvey Lodish (MIT/Whitehead Institute).
Dr. Shi has 20 years’ experience in the development of bio-therapeutics . He participated in vaccine development against hepatitis E virus (HEV), causing a type of viral hepatitis. The vaccine was commercialized under the trade name 益可宁 Hecolin in 2012. During his PhD studies, Dr. Shi developed novel strategies for drug development against Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV), by targeting its main protease (SARS-CoV Mpro). He demonstrated that the dimerization interface at the extra helical domain of SARS-CoV Mpro is an attractive drug targeting pocket. As this pocket is far from the active site of Mpro, drugs targeting this pocket will have minimum off-target effects to other human proteases. Given the similarity between SARS-CoV Mpro and COVID-19-CoV Mpro, such an approach might also be attractive for COVID-19.
When he was at the Lodish lab, Dr. Shi co-invented a new technology for engineering red blood cells as carriers for a wide range of therapeutic cargoes, particularly for therapeutic proteins. This invention led to the establishment of Rubius Therapeutics, which went public in 2018 and reached a market capitalization of almost 2 billion USD.
After setting up his own lab, Dr. Shi is focused on the development of novel therapeutics, including gene therapy, genome editing and antibody therapy. Working with his collaborators, Dr. Shi engineers red blood cell extracellular vesicles (RBCEV) as a non-viral gene delivery vehicle. Again, this innovation has led to the establishment of another biotech company, now based in Cambridge, Massachusetts, Carmine Therapeutics, co-founded with Harvey Lodish, Minh Le and EVX Ventures.
Dr. Shi aims to develop more novel therapies against unmet clinical needs. He is presently an Assistant Professor at the National University of Singapore.